73
Participants
Start Date
June 11, 2018
Primary Completion Date
July 5, 2019
Study Completion Date
July 5, 2019
ABI-H0731
Participants will receive ABI-H0731 300 mg tablets orally once daily (QD).
SOC NUC
Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet orally as per approved package insert.
Placebo Oral Tablet
Participants will receive placebo matching ABI-0731 tablets orally QD.
NYU Langone Health, New York
Icahn School of Medicine at Mount Sinai, New York
Sing Chan, MD, Flushing
Thomas Jefferson University Hospital, Philadelphia
Xiaoli Ma, MD, Philadelphia
Digestive Disease Associates, Catonsville
Johns Hopkins University School of Medicine, Baltimore
University of Miami Hospital and Clinics, Miami
Asia Pacific Liver Center, Los Angeles
University of California Los Angeles, Los Angeles
Cedars-Sinai Medical Center, Beverly Hills
Research and Education, San Diego
Southern California Research Center, Coronado
Medical Associates Research Group, San Diego
Quest Clinical Research, San Francisco
Stanford University Medical Center, Stanford
Infectious Disease Care, Hillsborough
Toronto General Hospital, Toronto
Toronto Liver Center, Toronto
GI Research Institute, Vancouver
Auckland City Hospital, Auckland
Lead Sponsor
Assembly Biosciences
INDUSTRY